• Formycon highlighted a peer-reviewed BioDrugs publication detailing its streamlined clinical program for Keytruda biosimilar candidate FYB206.
• Clinical results were already presented, with FYB206’s development completed in July 2026.
• The pivotal DAHLIA trial showed FYB206 matched Keytruda in pharmacokinetics, supporting biosimilarity without a traditional efficacy study.
• The approach positions PK-focused development as a lower-burden pathway that could speed timelines and reduce costs for selected biosimilars.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Formycon AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2402630_en) on September 22, 2026, and is solely responsible for the information contained therein.